Multisciplinary management of patients with liver metastasis from colorectal cancer by De Greef, Kathleen et al.
Multisciplinary management of patients with liver 
metastasis from colorectal cancer
Kathleen De Greef, Christian Rolfo, Antonio Russo, Thiery Chapelle, Giuseppe Bronte, Francesco Passiglia, 
Andreia Coelho, Konstantinos Papadimitriou, Marc Peeters 
Kathleen De Greef, Thiery Chapelle, Hepatobiliary, Transplant 
and endocrine surgery Department, Antwerp University Hospital, 
2650 Edegem, Belgium
Christian Rolfo, Francesco Passiglia, Andreia Coelho, 
Phase I - Early Clinical Trials Unit, Oncology Department and 
Multidisciplinary Oncology Center Antwerp, Antwerp University 
Hospital, 2650 Edegem, Belgium
Antonio Russo, Giuseppe Bronte, Francesco Passiglia, 
Department of Surgical, Oncological and Oral Sciences, Section 
of Medical Oncology, University of Palermo, 90133 Palermo, 
Italy
Andreia Coelho, Oncology Department, Centro Hospitalar de 
Trás-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal
Konstantinos Papadimitriou, Marc Peeters, Oncology 
Department and Multidisciplinary Oncology Center Antwerp, 
Antwerp University Hospital, 2650 Edegem, Belgium
Author contributions: De Greef K and Rolfo C wrote the 
manuscript; De Greef K, Rolfo C, Russo A, Chapelle T, Bronte 
G, Passiglia F, Coelho A, Papadimitriou K and Peeters M 
contributed to the content of the manuscript, revision and final 
manuscript approval; De Greef K, Rolfo C and Peeters M 
conceived the idea and manuscript format; De Greef K and Rolfo 
C contributed equally to this work.
Conflict-of-interest statement: The authors declare no conflict 
of interest for this paper.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Christian Rolfo, MD, PhD, Professor, Head 
of Phase I, Early Clinical Trials Unit, Oncology Department, Antwerp 
University Hospital, Wilrijkstraat 10, 2650 Edegem, 
Belgium. christian.rolfo@uza.be
Telephone: +32-3-8213646 
Received: March 7, 2016
Peer-review started: March 8, 2016
First decision: May 12, 2016
Revised: June 21, 2016
Accepted: August 1, 2016
Article in press: August 1, 2016
Published online: August 28, 2016
Abstract
Colorectal cancer (CRC) is one of the leading causes 
of cancer-related death. Surgery, radiotherapy and 
chemotherapy have been till now the main therapeutic 
strategies for disease control and improvement of the 
overall survival. Twenty-five per cent (25%) of CRC 
patients have clinically detectable liver metastases at 
the initial diagnosis and approximately 50% develop 
liver metastases during their disease course. Twenty-
thirty per cent (20%-30%) are CRC patients with 
metastases confined to the liver. Some years ago 
various studies showed a curative potential for liver 
metastases resection. For this reason some authors 
proposed the conversion of unresectable liver meta-
stases to resectable to achieve cure. Since those 
results were published, a lot of regimens have been 
studied for resectability potential. Better results could 
be obtained by the combination of chemotherapy 
with targeted drugs, such as anti-VEGF and anti-
EGFR monoclonal antibodies. However an accurate 
selection for patients to treat with these regimens and 
to operate for liver metastases is mandatory to reduce 
the risk of complications. A multidisciplinary team 
approach represents the best way for a proper patient 
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initially resectable disease; those with metastases 
that may become resectable following treatment 
(“conversion” therapy); and patients whose liver 
metastasis never will be resectable[10]. Unfortunaly, 
only a minority of patients (10%-20%) with CLM are 
considered eligible for resection, while about 85% of 
them have liver disease considered unresectable at 
presentation[11,12]. Recent data suggest that of those 
undergoing resection of CLM, around one out of three 
patients will be still alive after 5 years from diagnosis. 
A single center 5-years survival now approaches 60% 
following hepatectomy, with 10 years survival in excess 
of 25%; about half of them will be alive after 10 years, 
so considered as cured[13]. A systematic review and 
meta-analysis of 142 studies published in 1999-2010 
has also confirmed these data, showing 5-year survival 
rates of 16%-71%, for patients with CRC, after 
surgical resection of liver metastases[14]. Even more, 
long-term survival rates for those patients with initially 
unresectable metastases treated with chemotherapy 
prior to surgery are similar to those of patients whose 
metastases were considered to be resectable[15-21]. 
Indeed, since there is a strong correlation between 
tumor response and resection rate[3,22], this has 
led to an increased use of chemotherapeutic and 
biological agents as “conversion therapies” in patients 
with mCRC. Indeed, these strategies can facilitate 
downsizing of CLM and convert initial unresectable 
metastases to resectable. Hence, the percentage of 
patients potentially eligible for curative liver resection 
is increasing. This has been due to advances in surgical 
and perioperative management, the use of more 
effective chemotherapies and combination therapies, 
the incorporation of targeted therapies and new local 
treatment approaches (e.g., hepatic intra-arterial 
chemotherapy, RFA, stereotactic radiotherapy)[23]. 
Nonetheless, difficulties remain in deciding who is a 
candidate for resection, and often underestimated 
since many patients with liver metastasis never were 
referred to a hepatobiliary surgeon[24]. 
Therefore, the goal for patients with metastatic 
colorectal disease is a multidisciplinary treatment 
approach, in order to decrease peri-operative morbi-
dity and mortality, as well as long-time survival by 
increasing the number of patients undergoing potential 
curative liver resections.
RESECTION OF CLM - CURRENT 
EVIDENCES
Surgical treatment
Hepatectomy remains the standard of care for CLM. 
In the past, post-operative mortality was high but 
nowadays it has decreased to around 1%[25-27] allowing 
more extended hepatic resections by more advanced 
surgical techniques. Nevertheless, liver failure after 
hepatectomy remains the major concern for the 
hepatobiliary surgeon. Resection, even partial, can 
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management. The team needs to include surgeons, 
oncologists, diagnostic and interventional radiologists 
with expertise in hepatobiliary disease, molecular 
pathologists, and clinical nurse specialists. This review 
summarizes the most important findings on surgery and 
systemic treatment of CRC-related liver metastases. 
Key words: Liver metastases; Colorectal cancer; Liver 
resection; Multidisciplinary team; Chemotherapy
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Approximately 25% of colorectal cancer 
patients have liver metastases at the initial diagnosis 
and almost half develop liver metastases later. Although 
unresectable liver metastases can be converted into 
resectable disease with the help of combination 
chemotherapy with targeted therapy, patients should 
be accurately selected. Multidisciplinary teams including 
health professional with expertise in hepatobiliary 
disease is needed to decide the best way to manage 
these patients’ treatment. 
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INTRODUCTION
Globally, colorectal cancer (CRC) is the third most 
commonly diagnosed cancer in males and the second 
in females[1]. Moreover, CRC is the second leading 
cause of cancer mortality in the United States, 
accounting for 9% of cancer deaths[2]. In Europe, it 
caused nearly 204000 deaths in 2004[3]. The liver is 
the most common metastatic site[4], probably due 
to tumor spread via the portal system[5]. Twenty 
to twenty-five percent of patients have clinically 
detectable colorectal liver metastases (CLM) at the 
initial diagnosis and approximately 50% of the patients 
develop CLM during their disease course[6]. Resection 
of the CLM, sometimes in combination with other local 
treatment modalities such as radiofrequency ablation 
(RFA), has become the standard of care, despite lack 
of evidence from randomized controlled trials, and 
offers the only potential for cure[7,8]. The natural history 
of metastatic colorectal cancer (mCRC) is variable, 
however, untreated CLM have a poor prognosis with 
median survival rates of less than 8 mo[6,9]. Only 
20%-30% patients with mCRC have disease that is 
confined to the liver[6]. Patients presenting with CLM 
can generally be divided into three groups: those with 
result in a small postoperative remnant liver function, 
hence increasing the risk of postoperative liver failure 
and subsequent very high mortality. In 2006, a 
national multicenter study by the group of Schroeder 
et al[28] showed an overall mortality rate after 
hepatectomy of 8.5% in the perioperative period. This 
mortality rate increases up to 16% when performing 
an hepatectomy of 3 segments or more.
Below a critical liver volume, the remnant liver 
cannot sustain metabolic, synthetic, and detoxifying 
functions[29]. However liver volume is not the best 
surrogate for liver function, in particular for patients 
with concomitant liver disease[30,31]. Based on data from 
the transplantation literature, it has been postulated 
empirically that each percent increase in fat content, 
either microvesicular or macrovesicular, decreases the 
functional mass of a donor liver by 1%[32]. In patients 
with cirrhosis, with non-alcoholic steatohepatitis, with 
obstructing jaundice due to a tumor or livers after 
chemotherapy regeneration capacity may be impaired 
(Table 1).
Major partial hepatectomy in combination with 
underlying parenchymal disease correlate well with 
increased morbidity and mortality rates[33-37]. In several 
series, the overall liver failure rate leading to death 
ranges from 25% to 100% following hepatic resection 
for hepatocellular carcinoma (HCC)[38-42]. However 
patients with HCC mostly have underlying cirrhosis as 
an etiologic factor for their tumors. Instead mortality 
rates after resection for CRC have a wide range, with 
up to 50% of deaths from liver failure[43,44]. Prolonged 
recovery and also mortality can also occur for the same 
reason as for patients with HCC, further indicating the 
importance of liver reserve in recovery from hepatic 
surgery in patients who received chemotherapy[45]. 
Most chemotherapeutic agents, even 5-fluorouracil, 
can cause liver damage[15]. Some studies suggest 
that patients who receive chemotherapy develop 
steatosis[35,46-48] whereas others show no correlation 
between any chemotherapy regimen and severe 
steatosis[49]. Others found that irinotecan is associated 
with the development of steatohepatitis in some 
patients[49,50]. Therefore, successful liver resection 
implicates correct recognition of remnant liver function. 
The group of Van Gulik could nicely show that pre-
operative measurement of 99mTc-mebrofenin uptake 
in the future remnant liver on functional hepatobiliary 
scintigraphy proved more valuable than measurement 
of the volume of the future remnant in the assessment 
of the post-hepatectomy risk of liver failure and liver 
failure-related mortality[30,31,51,52].
In addition, sparing residual liver parenchyma should 
be of considerable importance in patients who received 
neo-adjuvant chemotherapy for CLM. The definition of 
what are resectable lesions is extremely variable and it 
depends on the experience and aggressiveness of the 
surgical team. A study of Lalmahomed et al[53], showed 
that patients treated with liver sparing resections, had 
to undergo more interventions for local recurrence than 
patients undergoing anatomical resections. Another 
population-based study in England showed that of 115 
patients undergoing surgery for CRC between 1998 
and 2004, 2.7% had minimum 1 hepatic resection. 
Another disadvantage of liver sparing resections 
was reported in the literature by DeMatteo et al[54] 
finding higher incidence of positive resection margins 
when performing liver sparing resections. Indeed, 
50% to 75% of patients develop disease recurrence 
after initially curative resection of CLM. Anatomical 
resections may not offer the same advantage for these 
lesions as for HCC, which arise within a segment of 
the liver and might benefit from the removal of the 
complete functional liver unit. Indeed, several studies 
in patients with CLM have been reported in which no 
significant difference in morbidity, mortality, recurrence 
rate, or survival according to resection type and liver 
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Table 1  Response and resection rates from trials with first-line chemo/biologic therapy
Study Selection Treatment Response Resection
Van Cutsem et al[88] 2009 Unselected Bevacizumab + chemotherapy (FOLFOX/FOLFIRI) NA 11.8%
6% (R0)
Okines et al[89] 2009 Unselected Bevacizumab + Oxaliplatin-based chemotherapy 38%   6.3%
Wong et al[90] 2011 Unselected Bevacizumab + XELOX 68% 48.0%
Loupakis et al[91] 2013 Unselected Bevacizumab + FOLFOXIRI 64% 15.0%
Martin et al[92] 2014 Unselected Bevacizumab + FOLFOX + DEBIRI 78% 35.0%
Bokemeyer et al[94] 2009 KRAS WT Cetuximab + FOLFOX 57%   7.3%
4.7 (R0)
Van Cutsem et al[95] 2011 KRAS WT Cetuximab + FOLFIRI 57% 16.0%
7% (R0)
Folprecht et al[22] 2010 KRAS WT Cetuximab + chemotherapy (FOLFOX/FOLFIRI) 68% 43.0%
34% (R0)
Garufi et al[96] 2010 KRAS WT Cetuximab + FOLFOXIRI 79% 60.0%
Ye et al[97] 2013 KRAS WT Cetuximab + FOLFOXIRI 57% 25% (R0)
Köhne et al[100] 2012 KRAS WT Panitumumab + FOLFIRI 56% 15.0%
Douillard et al[101] 2010 KRAS WT Panitumumab + FOLFOX 57% 27.0%
5.2% (R0)
NRAS WT Panitumumab + FOLFOX 31.0%
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NA: Not available.
was achieved in 38% of patients[75]. Treatment with 
5-FU/LV, oxaliplatin and irinotecan (FOLFOXIRI) 
regimens permitted R0, curative-intent resections, 
in 15% of patients, and 36% of patients with liver 
metastases only[76]. Recently, a randomized, phase Ⅱ 
trial, comparing intensified chemotherapy regimens 
(high-dose FOLFIRI, FOLFOX7, FOLFIRINOX) with 
standard chemotherapy regimens (FOLFOX4, FOLFIRI), 
for initially unresectable mCRC, has shown that 
FOLFIRINOX appears more active than other regimens 
(conversion rate to resectability: 67%; mOS > 48 
mo; all others < 30 mo). Furthermore, this trial has 
confirmed that patients who undergo R0/R1 resections 
do much better than non-operated, or R2 (R0/R1:
mOS > 65.2 mo; not-operated/R2:mOS: 18.3 mo, P < 
0.001)[77].
 For patients with resectable disease, “perioperative 
chemotherapy” has become an attractive option, 
in order to reduce the incidence of cancer relapse, 
occurring in up to 50%-70% of them after resection, 
through the eradication of occult disease[78,79]. Recently, 
the randomized, phase Ⅲ trial, EORTC 40983, 
comparing peri-operative (both neoadjuvant and 
adjuvant) FOLFOX4 chemotherapy with surgery alone 
in 364 patients with resectable CLM, has shown a 
significant increment of PFS, in favour of perioperative 
treatment, but no significant differences in long term 
OS between the two treatment arms[80]. In addiction, 
the risk of post-operative complications has been shown 
to be significantly more frequent in the chemotherapy 
arm compared with surgery alone, and also to correlate 
with the duration of perioperative treatment. Several 
trials currently ongoing, such as the EORTC trial 40091 
(NCT01508000) are investigating the combination 
of targeted agents such as Bevacizumab and Panitu-
mumab with FOLFOX-chemotherapy regimen in peri-
operative treatment of patients candidate for resection 
of CLM, but results are not available yet.
Targeted biological treatment
Our increased understanding of the biology of CRC has 
led to the development of biologic therapies targeting 
two different mechanisms, angiogenesis (bevacizumab) 
and epidermal growth factor receptors (EGFRs) (cetu-
ximab and pantumumab)[81]. One strategy to further 
increase the number of candidates eligible for surgery 
is the addition of active targeted agents to standard 
chemotherapy. In general, response rates appear to be 
highest with the EGFRIs, therefore these agents may 
potentially also lead to greater resection rates.
Resection rates with anti-angiogenesis agents: 
Bevacizumab
Addition of bevacizumab to first and second line 
chemotherapy for mCRC improves progression-free 
survival[82-85] and in some studies overall survival[83,84]. 
However, data on the role of bevacizumab added to 
chemotherapy in the perioperative setting are limited, 
sparing resections has been observed[55-57]. Moreover, 
the cure rate by initial hepatectomy is only 20% to 
30% of cases[58,59]. Several studies in patients with CLM 
reported no significant difference in morbidity, mortality, 
recurrence rate, or survival according to resection 
type[60-62]. Karanjia et al[63] showed that patients who 
underwent right and extended right hepatectomy had 
a poorer short-term outcome, with a higher incidence 
of operative morbidity and mortality, compared to 
patients, undergoing other types of surgical treatment 
for the same disease. The degree of hepatic resection 
seems to influence tumor growth. Indeed, growth 
factors such as hepatocyte growth factor, epidermal 
growth factor, and insulin-like growth factor are 
generally upregulated early in liver regeneration, 
producing a mitogenic response and resulting in rapid 
hepatocyte cell proliferation[64,65]. Some other studies 
with less than 50% hepatectomies showed no tumor 
growth stimulation[66,67]. A larger resection causes 
the liver to express higher levels of growth factors 
and cytokines to restore the liver to its functional 
size in approximately the same time as for a smaller 
hepatectomy[68-71]. A number of studies have found that 
the larger the percentage of resection, the higher the 
incidence and volume of recurrence[72,73]. In addition, as 
mentioned before, although neoadjuvant chemotherapy 
increases resectability for CLM, it is associated with 
hepatic changes, such as hepatic sinusoidal obstruction, 
periportal inflammation, and steatohepatitis, which can 
affect patient outcome[74] and which might increase the 
risk of progressive hepatic failure and death after major 
liver resection. An extensive resection can be tolerated 
with virtually no risk related if the underlying liver is 
normal. In contrast, even a minor hepatectomy can 
be dangerous in patients with severely compromised 
livers[46]. Actually, the assessment of the underlying 
liver function is critical for the type of surgery.
Given the implications of these recent advances that 
have extended the indications for hepatectomy in the 
treatment for CRC metastases, as well as the positive 
and negative effects of an extended liver resection, 
there is need of a multimodality approach to treat 
patients with metastatic liver disease. 
Chemotherapy treatment
In the last years the role of chemotherapy in the mana-
gement of CLM is considerably increased. Nowadays, 
it may be considered for both unresectable and 
resectable CLM. For patients with unresectable CLM, 
“conversion chemotherapy” aims to convert unresec-
table, to resectable disease, often representing the 
initial treatment choice. Standard regimens comprising 
5-FU/LV plus either irinotecan (FOLFIRI) or oxaliplatin 
(FOLFOX) can facilitate resection in 7%-40% of 
patients[24]. In 1999 the group of Giacchetti reported 
that 5-FU/LV plus oxaliplatin treatment could reduce 
the size of liver metastases by > 50% in 59% of the 
patients with unresectable CLM and complete resection 
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perhaps as a result of concerns about potential wound 
healing complications[86,87]. The Bevacizumab Expanded 
Access Trial showed that resection of hepatic metastasis 
after first-line bevacizumab plus chemotherapy was 
feasible and curative-intent hepatic resection of 
metastasis was performed in (11.8%) of patients overall 
(R0 in 6%)[88]. However, resection rates were higher 
in patients treated with bevacizumab plus Oxaliplatin 
chemotherapy (16.1%), than in those treated with 
bevacizumab plus Irinotecan chemotherapy (9.7%).
In a further first-line trial comparing oxaliplatin 
based chemotherapy plus bevacizumab or placebo, 
6.3% of patients with bevacizumab and 4.9% of 
those treated with placebo underwent R0 resection 
of the metastasis (P = 0.24)[89]. Another study of 
neoadjuvant CAPOX plus bevacizumab allowed 12 
out of 30 (40%) patients with initially unresectable 
CLM to be converted to resectable[90]. Loupakis et al[91] 
have recently reported a RR of 64% and a resection 
rate of 15%, in patients treated with FOLFOXIRI plus 
bevacizumab, as compared with respectively 53% and 
12%, of those treated with FOLFIRI plus bevacizumab. 
Finally, the combination of intra-arterial infusion of 
irinotecan-loaded drug-eluting beads (DEBIRI), with 
the FOLFOX plus Bevacizumab regimen, led to a 78% 
RR, and 35% of downsizing to resection, in patients 
with unresectable, liver-limited CRC, representing a 
new, promising, treatment strategies in this subset of 
patients[92].
Resection rates with anti-EGFR agents: Cetuximab and 
panitumumab
Anti-EFGR agents, cetuximab and panitumumab, are 
active both as single agents as well as in combination 
with chemotherapy in mCRC, with activity is confined 
to patients with RAS (both KRAS and NRAS) wild type 
tumors[93]. Five key randomized trials have evaluated 
the effects of cetuximab in patients with unresectable 
liver metastasis: (1) OPUS (Oxaliplatin and cetuximab in 
first-line treatment of MCRC)[94]. Addition of cetuximab 
to FOLFOX-4 almost doubled the R0 resection rate 
from 2.4% (FOLFOX-4 alone) to 4.7% (cetuximab plus 
FOLFOX-4); (2) CRYSTAL (cetuximab combined with 
irinotecan in first-line therapy for MCRC)[95]. Addition 
of cetuximab to FOLFIRI led an increase in the R0 
resection rate from 3.7% to 7.0%; (3) colorectal Liver 
Metastases (CELIM)[22]. Patients received neoadjuvant 
treatment with cetuximab plus either FOLFIRI or 
FOLFOX6 and resections were performed in 43% 
of patients overall; 34% had RO resections; (4) 
POCHER (Cetuximab plus chronomodulated irinotecan, 
5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant 
chemotherapy in CLM)[96]; and (5) a Randomized 
Controlled Trial of Cetuximab Plus Chemotherapy for 
Patients With KRAS Wild-Type, Unresectable, Colorectal 
Liver-Limited Metastases, has recently shown that the 
addiction of Cetuximab to chemotherapy, significantly 
improved the R0 resection rate (25.7% vs 7.4%, P = 
0.01)[97]. 
We need to discuss the reasons for the discrepancies 
in secondary liver resection rates in KRAS WT liver 
limited disease between these five studies following CT 
+ Cetuximab. Overall RR was 60%-79% across these 
5 studies but hepatectomy rates after CT + Erbitux 
was 9% in OPUS; 16% in CRYSTAL, 43% (33%R0) 
in CELIM, 60% in POCHER, and 25% in the recent 
Chinese trial. In the latter studies, resectability was 
detected by a multidisciplinary team, including a liver 
surgeons, while in CRYSTAL and OPUS, it was detected 
by non-specialist oncologists.
Two other randomized trials (COIN[98] and NORDIC 
Ⅶ[99]), have recently shown that Cetuximab adds no 
benefit to the Oxaliplatin chemotherapy regimen, in 
first-line treatment of mCRC, irrespectively of K-RAS 
status, even if in the COIN study cetuximab resulted in 
a higher response rate in patients with wild-type KRAS 
tumors[98].
Resection rates have also been reported in first-line 
panitumumab trials in patients with mCRC. Indeed, in a 
phase Ⅱ single-arm study, panitumumab plus FOLFIRI 
treatment resulted in resection rates of 15% vs 7% in 
the KRAS WT and mutant (MT) groups, respectively[100]. 
In a large, randomized phase Ⅲ study, of the 16% of 
patients with liver-limited disease, R0 resections were 
achieved in 32% of patients receiving FOLFOX4 plus 
panitumumab vs 28% of those receiving FOLFOX4 
alone[101]. Baseline resectability was not recorded and 
so conversion rates could not be assessed. However, 
in a subsequent post-hoc analysis of the PRIME study, 
including RAS WT (both KRAS and NRAS) patients 
with liver metastasis only, Panitumumab plus FOLFOX 
resulted in conversion of about one-third of initially 
unresectable patients, enabling metastasectomy in 
31% and complete resection in 29%, compared with 
22% metastasectomy and 17% complete resection in 
the chemotherapy arm[102]. Recently, a retrospective-
prospective analysis of PRIME study has shown that 
NRAS mutations predicted a lack of response to anti-
EGFR Panitumumab. Infact, the subgroup of patients 
reporting NRAS mutations, representing 17% of non-
mutated KRAS population, reported inferior outcomes, 
which were consistent with the outcomes of the KRAS 
mutated patients[93]. This highlights the importance 
for detecting other RAS mutations to better select a 
subgroup of patients most likely to benefit from anti-
EGFR Mabs.
USE OF RESECTION IN CLINICAL 
PRACTICE
Patient selection
Difficulties remain in deciding who is resectable in 
clinical practice. Most liver surgeons accept the current 
AHPBA consensus on definition of resectability[103]. 
Until recently, CLM resection was mostly offered to 
those patients with liver-only disease that was (ideally) 
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detected metachronously after curative resection of 
the primary tumor, confined to one lobe of the liver, 
had less than 3 metastases, the largest of which was 
smaller than 5 cm in diameter. These patients need 
to have a margin of healthy liver tissue of more than 
1 cm[104,105]. This would restrict CLM resection to < 
10% of patients with liver-limited disease. Although 
the definition of resectable disease is broadening, 
patient selection guidelines for resection of CLM 
remain controversial, with an increase in aggressive 
management approach being used in recent years[8]. 
The criteria for CLM resectability are not standardized 
and are related to the experience of the surgeon and 
of the multidisciplinary team (MDT). Different teams 
and surgeons might approach the same patient 
differently. Current guidelines state that resection 
should be considered for solitary or confined liver 
metastases[24]. The remaining liver also needs to be 
healthy (viable vascular inflow and biliary and vascular 
outflow) and represent 20%-25% of liver volume at 
presentation[106]. Extra-hepatic disease is no longer an 
absolute contraindication for CLM resection[27]. This 
means that at least 20% of patients with liver-only 
disease are now considered candidates for resection. 
Multiple resections can also be safely performed if 
there is sufficient healthy remnant liver[12] and the 
risks of surgery are not too great. Survival benefit 
following repeat resection appears similar to that 
following the first liver resection[107,108]. General factors 
that influence safe liver resection include patient age, 
performans status, and concurrent parenchymal 
liver disease. Contraindications include unresectable 
extrahepatic disease, significant parenchymal liver 
disease, or patient unfit to undergo the procedure[12]. 
As difficulties remain in deciding who is resectable, 
many studies have examined potential prognostic 
factors for outcome following resection, with the aim 
of developing preoperative criteria for the selection of 
patients who may benefit from resection of CLM. Many 
clinical and pathological factors have been evaluated 
as potential prognostic determinants of survival after 
surgical resection of CLM. Such as: age, sex, primary 
tumor stage, synchronous or metachronous hepatic 
metastases, extrahepatic distant metastases, surgical 
margin, tumor size, number and distribution of CLM; 
carcinoembryonic antigen level, type of hepatectomy, 
and adjuvant chemotherapy. In Japan, Fong et al 
evaluated clinical, pathologic and outcome data for 
1001 patients with mCRC undergoing resection[109]. 
Seven criteria were identified that predicted for worse 
prognosis after resection. Five of these were subse-
quently chosen for a preoperative scoring system (the 
Clinical Risk Score). These were: node-positive primary, 
disease-free interval from primary to metastases < 
12 mo, number of hepatic tumors > 1, largest hepatic 
tumor > 5 cm, and carcinoembryonic antigen level 
> 200 ng/mL. Patients with a score less than 2 had 
favorable prognostic characteristic after resection, 
scores of 3-4 were considered candidates for resection 
followed by adjuvant therapy. Prognosis was poor for 
those with scores of 5. This Clinical Risk Score has 
subsequently been validated and found to be highly 
predictive of patient outcome and survival[110]. More 
recently another scoring system was developed in 
Japan[111,112]. This, included six variables which showed 
overlap with those used in the Clinical Score (mul-
tiple tumors, the largest tumor > 5 cm in diameter, 
resectable extrahepatic metastases, serosa invasion, 
local lymph node metastases of primary cancers, and 
postoperative disease free interval of less than 1 year 
including synchronous hepatic metastasis). In line with 
the criteria mentioned above, a recent population-
based study of patients with isolated CLM, increasing 
age, poor performance status, and high initial tumor 
burden were all associated with a decreased rate of 
referral to a hepatobiliary surgeon[8]. Novel qualitative 
morphologic criteria by CT evaluation have also been 
identified to predict the response to bevacizumab-
containing chemotherapy in patients with CLM[113]. More-
over, the optimal response to preoperative treatment 
according to these morphologic criteria translated into 
a survival benefit following hepatic resection. Finally, 
a recent study by Karagkounis et al[114], consistently 
with the findings of other 3 studies[115-117], has shown 
that both RAS and BRAF mutations are associated 
with a worse prognosis after resection of CLM. These 
interesting evidences support the introduction of new 
treatment decision models in the management of 
CRC patients with liver metastatic disease, taking into 
account the new molecular factors as indicators of 
“biological resectability”, together with the other clinical-
pathological factors, in order to predict the outcomes of 
patients undergoing resection of CLM, and select good 
candidates for surgery. 
MDT APPROACH TO PATIENT 
MANAGEMENT
Patients with cancer have complex needs and so their 
care cannot be addressed optimally by a single specialty 
or discipline. To ensure the optimal management and 
treatment of patients with mCRC throughout their 
treatment history, a MDT approach is now the norm 
in most European countries. Colorectal MDTs should 
also identify/establish a specialised hepatobiliary MDT 
that can provide the required additional expertise 
and facilities for patients with CLM[6]. Some studies 
in patients with liver-only metastases have showed 
improved survival among patients undergoing resec-
tion who are managed by a MDT including a liver 
surgeon[118,119]. The MDT would normally comprise 
two or more specialist surgeons with a high level of 
skills and training in liver resection surgery. Other 
team members may include an oncologist, diagnostic 
and interventional radiologists with expertise in 
hepatobiliary disease, a histopathologist, and clinical 
nurse specialist[6]. There should be regular interaction 
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and discussion within the MDT to ensure that resection 
is utilized where appropriate and to ensure that 
patients not initially considered resectable are brought 
into the resectable category wherever possible. For 
example the MDT should be consulted regarding choice 
of combination chemotherapy and targeted agents, 
duration of chemotherapy break before/after surgery, 
care choices and follow-up screening etc. 
Thus, patients with mCRC may see a colorectal 
surgeon, a liver surgeon, and a medical oncologist 
to define optimal therapy. Medical oncologists should 
use the most active treatment for the shortest time 
by combination of chemotherapeutic regimens and 
targeted drugs to achieve tumor shrinkage without 
harming the normal liver. Defining the acceptable 
residual functioning liver volume may require assess-
ment by a radiologist working with a liver surgeon[6]. 
Resection can be useful even at later lines of therapy 
and so it is important that the MDT is consulted at 
each stage of a patient’s treatment. Repeat resection 
can be safely and effectively performed with survival 
races similar to those following initial resection[107,108,120]. 
Throughout the patient’s disease course, the clinical 
nurse specialist/nurse practitioner is key to providing 
them with advice, support and information. 
CONCLUSION
Patients with pretreated mCRC have few treatment 
options available, resection of metastatic disease 
is the only potentially curative strategy. Criteria for 
resectability have changed in recent years leading to 
an increased use of resection in patients with mCRC. 
No OS differences between simultaneous resection 
and staged resection of the primary tumour and 
resectable synchronous liver metastases. Increasing 
data suggest that biological agents (alone of combined 
with chemotherapy)-especially those targeting the 
EGFR-may be particularly useful in facilitating resection 
of liver metastases. Molecular biomarkers (first KRAS, 
and more recently NRAS), influences dramatically the 
anti-EGFR Mab activity and their identification have 
become mandatory for proper treatment planning 
in oncology. No OS benefit to adding perioperative 
chemotherapy to surgery for resectable liver meta-
stases. Patients with mCRC should be managed 
by a MDT to ensure optimal treatment choices are 
made over their disease course, including optimizing 
opportunities for potentially curative resection of 
metastatic disease.
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